PS1Nicastrin Interaction and Role in Trafficking
About the Research Project
Program
Award Type
Standard
Award Amount
$199,939
Active Dates
April 01, 2001 - March 31, 2003
Grant ID
A2001074
Summary
It is well known that presenilin proteins (PS-1 and PS-2) and other proteins interact to generate amyloid beta protein. Recently, researchers at the University of Toronto (with whom Dr. Thinakaran is collaborating) identified one of the proteins, Nicastrin, that interacts with presenilins. A better understanding of the association between presenilins and Nicastrin will shed more light on the mechanisms involved in amyloid beta production, and perhaps lead to new therapies for AD aimed at reducing amyloid beta deposits in the brain. Some studies also indicate that presenilins may be involved in assisting APP (the precursor for amyloid beta) in reaching appropriate destinations within the cell. Dr. Thinakaran is examining whether presenilins direct other proteins to their destinations. He will explore this issue by studying two proteins that resemble APP and others that have structures different from that of APP. It is hoped that these latter studies will help scientists understand what presenilins normally do. The information gained from studies like this will be critical to determining whether presenilins can be considered as appropriate targets for the treatment of AD.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD